Please login to the form below

Not currently logged in
Email:
Password:

Kevzara

This page shows the latest Kevzara news and features for those working in and with pharma, biotech and healthcare.

Dupixent gains can’t keep Sanofi on a growth track

Dupixent gains can’t keep Sanofi on a growth track

At the same time, some much-trumpeted new launches like cholesterol drug Praluent (alirocumab) and arthritis drug Kevzara (sarilumab) have not delivered on their potential. ... There were some encouraging signs in the third-quarter beyond Dupixent,

Latest news

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics